Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Oberarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell CarcinomaIn: European Journal of Cancer (EJC) , Jg. 217 2025, 115254
-
Correction : Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsIn: Journal of Translational Medicine , Jg. 23 2025, Nr. 1, 596DOI (Open Access)
-
Early switch from run-in with targeted to immunotherapy in advanced BRAFV⁶⁰⁰-positive melanoma: final results of the randomised phase II ImmunoCobiVem trialIn: ESMO Open , Jg. 10 2025, Nr. 5, 105053DOI (Open Access)
-
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaIn: Journal of the European Academy of Dermatology and Venereology 2025 , in pressDOI (Open Access)
-
Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patientsIn: Journal of Translational Medicine , Jg. 23 2025, Nr. 1, 532DOI (Open Access)
-
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy : A multicenter study on 2419 patients from the prospective skin cancer registry ADORegIn: European Journal of Cancer (EJC) , Jg. 214 2025, 115159DOI (Open Access)
-
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaIn: European Journal of Cancer (EJC) , Jg. 215 2025, 115171
-
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusIn: Frontiers in Immunology , Jg. 16 2025, 1536642DOI (Open Access)
-
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 23 2025, Nr. 3, S. 321 – 327DOI (Open Access)
-
Real‐world management bei Patienten mit Komplettremission unter Immuncheckpoint‐Inhibition bei fortgeschrittenem MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 23 2025, Nr. 3, S. 321 – 329DOI (Open Access)
-
pTERT mutational status is associated with survival in stage IV melanoma patients receiving first-line immune therapyIn: European Journal of Cancer (EJC) , Jg. 220 2025, 115337DOI (Open Access)
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC) , Jg. 202 2024, 113976DOI (Open Access)
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) , Jg. 200 2024, 113536DOI (Open Access)
-
Case report: : Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabIn: Frontiers in Immunology , Jg. 15 2024, 1369190DOI, Online Volltext (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology , Jg. 15 2024, 1383125DOI (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 210 2024, 114295DOI (Open Access)
-
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma : An analysis of the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) , Jg. 198 2024, 113508DOI (Open Access)
-
Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyIn: European Journal of Cancer (EJC) , Jg. 199 2024, 113561
-
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanomaIn: Science Advances , Jg. 10 2024, Nr. 48, eadp4670DOI (Open Access)
-
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma : A multicenter study on 1383 patients of the prospective DeCOG registry ADORegIn: International Journal of Cancer , Jg. 155 2024, Nr. 10, S. 1808 – 1823DOI (Open Access)
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity : a multicenter case seriesIn: Journal for ImmunoTherapy of Cancer , Jg. 12 2024, Nr. 1, e008232DOI (Open Access)
-
Nebenwirkungen dermatoonkologischer Therapien : Side effects of dermato-oncologic therapiesIn: Die Dermatologie , Jg. 75 2024, S. 466 – 475
-
Nebenwirkungen onkologischer TherapienIn: Die Dermatologie , Jg. 75 2024, Nr. 6, S. 437 – 439DOI (Open Access)
-
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapyIn: European Journal of Cancer (EJC) , Jg. 199 2024, 113563
-
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 203 2024, 114028DOI (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) , Jg. 208 2024, 114208DOI (Open Access)
-
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicityIn: Frontiers in Cardiovascular Medicine , Jg. 11 2024, 1408586DOI (Open Access)
-
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrationsIn: European Journal of Cancer (EJC) , Jg. 202 2024, 113984DOI (Open Access)
-
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 196 2024, 113441
-
The side effect registry immuno-oncology (SERIO) : A tool for systematic analysis of immunotherapy-induced side effectsIn: European Journal of Cancer (EJC) , Jg. 199 2024, 113505
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O) : disease-free survival results from a randomised, open-label, phase 2 trialIn: Lancet , Jg. 402 2023, Nr. 10404, S. 798 – 808
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC) , Jg. 191 2023, 112957
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1395DOI (Open Access)
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 11 2023, Nr. 4DOI (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) , Jg. 183 2023, S. 1 – 10
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: eBioMedicine , Jg. 96 2023, 104774DOI (Open Access)
-
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma : The ImmunoCobiVem phase 2 randomised trialIn: European Journal of Cancer (EJC) , Jg. 190 2023, 112941
-
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 181 2023, S. 188 – 197
-
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 186 2023, S. 12 – 21
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) , Jg. 188 2023, S. 140 – 151DOI, Online Volltext (Open Access)
-
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsIn: Med , Jg. 4 2023, Nr. 2, S. 113 – 129.e7DOI (Open Access)
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer , Jg. 4 2023, Nr. 9, S. 1292 – 1308DOI (Open Access)
-
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint InhibitionIn: Cancers , Jg. 15 2023, Nr. 13, 3448DOI (Open Access)
-
Neues ADO-Komitee „Survivorship“In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. 10, S. 1266 – 1267DOI (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice , Jg. 2 2023, Nr. 4, S. 810 – 818DOI, Online Volltext (Open Access)
-
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaIn: Current Oncology Reports , Jg. 25 2023, Nr. 6 , :647-657DOI (Open Access)
-
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabIn: Journal of Translational Medicine , Jg. 21 2023, Nr. 1, 753DOI (Open Access)
-
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch : A Multicenter, Retrospective StudyIn: Cancers , Jg. 15 2023, Nr. 5, 1426DOI (Open Access)
-
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy : A multicenter study from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 11 2023, Nr. 9, e007630DOI (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet , Jg. 400 2022, Nr. 10358, S. 1117 – 1129
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology , Jg. 12 2022, 879876DOI, Online Volltext (Open Access)
-
CTLA-4 Blockade Resistance after Relatlimab and NivolumabIn: The New England Journal of Medicine , Jg. 386 2022, Nr. 17, S. 1668 – 1669DOI (Open Access)
-
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis : A retrospective multicentre cohort studyIn: European Journal of Cancer (EJC) , Jg. 175 2022, S. 224 – 235DOI (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology , Jg. 36 2022, Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 – 44DOI (Open Access)
-
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma : a retrospective multicentre analysisIn: European Journal of Cancer (EJC) , Jg. 162 2022, S. 22 – 33
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine , Jg. 12 2022, Nr. 11, e1090DOI, Online Volltext (Open Access)
-
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 1, e003198DOI, Online Volltext (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research , Jg. 35 2022, Nr. 6, S. 573 – 586DOI (Open Access)
-
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisIn: Data in Brief , Jg. 45 2022, 108649DOI (Open Access)
-
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanomaIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 7, e004610DOI (Open Access)
-
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 7DOI (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers , Jg. 14 2022, Nr. 9, 2090DOI, Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers , Jg. 14 2022, Nr. 17, 4066DOI, Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer , Jg. 151 2022, Nr. 9, S. 1542 – 1554DOI (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) , Jg. 166 2022, S. 60 – 72
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 6, e004509DOI (Open Access)
-
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma : A multicenter study of the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer , Jg. 10 2022, Nr. 11, e005930DOI (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology , Jg. 36 2022, Nr. S1, S. 29 – 34DOI (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging , Jg. 22 2022, Nr. 1DOI, Online Volltext (Open Access)
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaIn: Clinical Cancer Research , Jg. 28 2022, Nr. 14, S. 3002 – 3010DOI (Open Access)
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts : Implications for Adjuvant TreatmentIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 32, S. 3741 – 3749DOI (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) , Jg. 63 2022, Nr. 3, S. 396 – 398DOI (Open Access)
-
Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapyIn: ESC Heart Failure , Jg. 9 2022, Nr. 5, S. 3533 – 3542DOI, Online Volltext (Open Access)
-
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma : An international, retrospective, cohort studyIn: Annals of Oncology , Jg. 33 2022, Nr. 9, S. 968 – 980
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) , Jg. 161 2022, S. 99 – 107DOI (Open Access)
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal , Jg. 43 2022, Nr. 4, S. 316 – 329
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) , Jg. 23 2022, Nr. 6, 3324DOI, Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology , Jg. 11 2021, 725549DOI, Online Volltext (Open Access)
-
Case Report : Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant MelanomaIn: Frontiers in Oncology , Jg. 11 2021, S. 637185DOI, Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) , Jg. 152 2021, S. 139 – 154
-
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibitionIn: Journal for ImmunoTherapy of Cancer , Jg. 9 2021, Nr. 1, e001931DOI (Open Access)
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) , Jg. 150 2021, S. 119 – 129
-
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanomaIn: Annals of Oncology , Jg. 32 2021, Nr. 7, S. 917 – 925DOI (Open Access)
-
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapyIn: eNeurologicalSci , Jg. 22 2021, 100324DOI (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology , Jg. 11 2021, 741993DOI, Online Volltext (Open Access)
-
Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg studyIn: Cancers , Jg. 13 2021, Nr. 10, S. 2312DOI (Open Access)
-
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma : A Retrospective Multicenter DeCOG StudyIn: Frontiers in Oncology , Jg. 11 2021, 672172DOI (Open Access)
-
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV⁶⁰⁰ mutant melanoma : safety and tolerability results from the phase I IMMU-TARGET trialIn: European Journal of Cancer (EJC) , Jg. 158 2021, S. 72 – 84
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers , Jg. 13 2021, Nr. 10, S. 2319DOI, Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology , Jg. 11 2021, 765608DOI, Online Volltext (Open Access)
-
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 147 2021, S. 170 – 181
-
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyIn: European Journal of Cancer (EJC) , Jg. 153 2021, S. 168 – 178
-
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy : A multicentre, retrospective, cohort studyIn: The Lancet Oncology , Jg. 22 2021, Nr. 6, S. 836 – 847
-
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma : Authors' replyIn: The Lancet Oncology , Jg. 22 2021, Nr. 8, S. E343 – E344
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt , Jg. 72 2021, Nr. 9, S. 801 – 804DOI (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) , Jg. 148 2021, S. 395 – 404
-
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy : A multicentre study of 90 patients from the German Dermatooncology GroupIn: European Journal of Cancer (EJC) , Jg. 149 2021, S. 1 – 10
-
Melanoma recurrence patterns and management after adjuvant targeted therapy : A multicentre analysisIn: British Journal of Cancer (BJC) , Jg. 124 2021, Nr. 3, S. 574 – 580DOI (Open Access)
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. 8, S. 1217 – 1219DOI (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) , Jg. 148 2021, S. 340 – 347DOI (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 159 2021, S. 113 – 124
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) , Jg. 148 2021, S. 61 – 75
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology , Jg. 147 2021, Nr. 6, S. 1763 – 1771DOI (Open Access)
-
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapyIn: European Journal of Cancer (EJC) , Jg. 153 2021, S. 213 – 222
-
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastasesIn: European Journal of Cancer (EJC) , Jg. 156 2021, S. 149 – 163DOI (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research , Jg. 27 2021, Nr. 16, S. 4500 – 4510DOI (Open Access)
-
SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registryIn: European Journal of Cancer (EJC) , Jg. 144 2021, S. 382 – 385
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) , Jg. 143 2021, S. 43 – 45
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) , Jg. 155 2021, S. 268 – 280
-
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition : A multicentre retrospective analysisIn: European Journal of Cancer (EJC) , Jg. 151 2021, S. 72 – 83DOI (Open Access)
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet , Jg. 395 2020, Nr. 10236, S. 1558 – 1568
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine , Jg. 26 2020, Nr. 7, S. 1147DOI (Open Access)
-
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyIn: PLoS Pathogens , Jg. 16 2020, Nr. 3, e1008340DOI (Open Access)
-
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis : A DeCOG∗ study in 380 patientsIn: Journal for ImmunoTherapy of Cancer , Jg. 8 2020, Nr. 1DOI (Open Access)
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer (EJC) , Jg. 131 2020, S. 18 – 26
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology , Jg. 10 2020, S. 592609DOI, Online Volltext (Open Access)
-
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine (JCM) , Jg. 9 2020, Nr. 7, 2060DOI, Online Volltext (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology , Jg. 31 2020, Nr. 1, S. 144 – 152DOI (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 10, S. 1165 – 1168DOI (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD , Jg. 183 2020, Nr. 5, S. 928 – 939DOI (Open Access)
-
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer , Jg. 8 2020, Nr. 2, S. e000897DOI (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist , Jg. 61 2020, Nr. 7, S. 669 – 675DOI (Open Access)
-
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer , Jg. 8 2020, Nr. 1, S. e000395DOI (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe , Jg. 26 2020, Nr. 8, S. 713 – 720
-
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom : ein UpdateIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 6, S. 582 – 609DOI (Open Access)
-
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma : real-world data of a retrospective, multicenter studyIn: European Journal of Cancer (EJC) , Jg. 138 2020, S. 125 – 132
-
S3 Guideline for the Diagnosis, Therapy and Follow‐Up of Malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 10, S. 1079 – 1208DOI (Open Access)
-
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an updateIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. 6, S. 582 – 609DOI (Open Access)
-
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer (EJC) , Jg. 130 2020, S. 126 – 138
-
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: The Journal of Dermatology , Jg. 47 2020, Nr. 6, S. 629 – 635
-
Checkpoint Inhibitors : The diagnosis and treatment of side effectsIn: Deutsches Ärzteblatt international , Jg. 116 2019, Nr. 8, S. 119 – 126DOI (Open Access)
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) , Jg. 119 2019, S. 66 – 76DOI (Open Access)
-
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases : a real-life multicenter studyIn: Melanoma Research , Jg. 29 2019, Nr. 1, S. 65 – 69DOI (Open Access)
-
Combined immune checkpoint blockade for metastatic uveal melanoma : a retrospective, multi-center studyIn: Journal for ImmunoTherapy of Cancer , Jg. 7 2019, Nr. 1 , Article-No: 299DOI (Open Access)
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 17 2019, Nr. Suppl. 5, S. 7 – 7
-
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer (EJC) , Jg. 119 2019, S. 18 – 29
-
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesIn: European Journal of Cancer (EJC) , Jg. 110 2019, S. 11 – 20DOI (Open Access)
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine , Jg. 25 2019, Nr. 12, S. 1916 – 1927DOI (Open Access)
-
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition : a case seriesIn: Cancer Immunology, Immunotherapy , Jg. 68 2019, Nr. 6, S. 983 – 990DOI (Open Access)
-
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks : An international rare cancers initiative (IRCI) ocular melanoma studyIn: Annals of Oncology , Jg. 30 2019, Nr. 8, S. 1370 – 1380DOI (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer , Jg. 7 2019, Nr. 1, S. 141DOI, Online Volltext (Open Access)
-
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) , Jg. 106 2019, S. 12 – 23
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology , Jg. 30 2019, Nr. 2, S. 317 – 324DOI (Open Access)
-
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery , Jg. 56 2019, Nr. 6, S. 1104 – 1109DOI (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer (EJC) , Jg. 109 2019, S. 137 – 153
-
Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case reportIn: BMC Cancer , Jg. 19 2019, Nr. 1, S. 995DOI, Online Volltext (Open Access)
-
Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsIn: Journal of Clinical Oncology (JCO) , Jg. 37 2019, Nr. 33, S. 3142 – 3151DOI (Open Access)
-
Tolerability of BRAF/MEK inhibitor combinations : Adverse event evaluation and managementIn: ESMO Open , Jg. 4 2019, Nr. 3, S. e000491DOI (Open Access)
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology , Jg. 30 2019, Nr. 4, S. 501 – 503DOI (Open Access)
-
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionIn: European Journal of Cancer (EJC) , Jg. 104 2018, S. 137 – 144DOI (Open Access)
-
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsIn: British Journal of Cancer (BJC) , Jg. 118 2018, Nr. 6, S. 785 – 792DOI (Open Access)
-
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 95 2018, S. 104 – 108
-
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disordersIn: Cancer Immunology, Immunotherapy , Jg. 67 2018, Nr. 5, S. 825 – 834
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer (EJC) , Jg. 99 2018, S. 58 – 65
-
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanomaIn: Cancer Medicine , Jg. 7 2018, Nr. 1, S. 95 – 104DOI (Open Access)
-
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma : A retrospective multicenter studyIn: OncoTarget , Jg. 9 2018, Nr. 76, S. 34336 – 34346DOI (Open Access)
-
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety , Jg. 17 2018, Nr. 1, S. 73 – 87
-
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4) : Evaluation and management of adverse drug reactionsIn: Cancer Treatment Reviews , Jg. 57 2017, S. 36 – 49
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer (EJC) , Jg. 86 2017, S. 248 – 256
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) , Jg. 83 2017, S. 142 – 145
-
IRF4 rs12203592 functional variant and melanoma survivalIn: International Journal of Cancer , Jg. 140 2017, Nr. 8, S. 1845 – 1849
-
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaIn: European Journal of Cancer (EJC) , Jg. 75 2017, S. 47 – 55
-
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityIn: European Journal of Cancer (EJC) , Jg. 75 2017, S. 24 – 32
-
Radiosensibilisierung durch BRAF InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 15 2017, Nr. 7, S. 703 – 708
-
Radiosensitization by BRAF inhibitorsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 15 2017, Nr. 7, S. 703 – 708
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology , Jg. 30 2017, Nr. 7, S. 928 – 939DOI (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget , Jg. 8 2017, Nr. 25, S. 40683 – 40692DOI (Open Access)
-
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyIn: European Journal of Cancer (EJC) , Jg. 60 2016, S. 190 – 209
-
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyIn: Cancer Treatment Reviews , Jg. 45 2016, S. 7 – 18
-
Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen StudieIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 14 2016, Nr. 5, S. 508 – 513
-
Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survivalIn: International Journal of Cancer , Jg. 139 2016, Nr. 6, S. 1297 – 1302DOI (Open Access)
-
Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosisIn: Medicine , Jg. 95 2016, Nr. 29, S. e4332DOI (Open Access)
-
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 14 2016, Nr. 7, S. 662 – 681
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT) , Jg. 34 2016, Nr. 1-2, S. 14 – 22
-
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten MelanomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 14 2016, Nr. 7, S. 662 – 683
-
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyIn: European Journal of Cancer (EJC) , Jg. 60 2016, S. 210 – 225
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC) , Jg. 57 2016, S. 112 – 117
-
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemIn: Journal of Neuro-Oncology , Jg. 127 2016, Nr. 3, S. 435 – 444DOI (Open Access)
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology , Jg. 26 2015, Nr. 3, S. 573 – 582DOI (Open Access)
-
Acquired BRAF inhibitor resistance : A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsIn: European Journal of Cancer (EJC) , Jg. 51 2015, Nr. 18, S. 2792 – 2799DOI (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget , Jg. 6 2015, Nr. 28, S. 25868 – 25882DOI (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 13 2015, Nr. Suppl. 2, S. 11
-
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?In: Melanoma Research , Jg. 25 2015, Nr. 4, S. 362 – 366
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE , Jg. 10 2015, Nr. 4, S. e0124590DOI (Open Access)
-
Erythema nodosum-like lesions during BRAF inhibitor therapy : report on 16 new cases and review of the literatureIn: Journal of the European Academy of Dermatology and Venereology , Jg. 29 2015, Nr. 9, S. 1797 – 1806
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanomaIn: Science , Jg. 350 2015, Nr. 6257, S. 207 – 211DOI (Open Access)
-
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanomaIn: Journal of Translational Medicine , Jg. 13 2015, Nr. 1, S. 351DOI (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE , Jg. 10 2015, Nr. 3, S. e0118564DOI (Open Access)
-
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology , Jg. 26 2015, Nr. 6, S. 1238 – 1244DOI (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology , Jg. 26 2015, Nr. 1, S. 250 – 251
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology , Jg. 25 2014, Nr. 3, S. 747 – 753
-
Genetic and clinico-pathologic analysis of metastatic uveal melanomaIn: Modern Pathology , Jg. 27 2014, Nr. 2, S. 175 – 183
-
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaIn: Journal of Clinical Oncology (JCO) , Jg. 32 2014, Nr. 8, S. 816 – 823
-
Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-InhibitorenIn: Der Hautarzt , Jg. 65 2014, Nr. 7, S. 582 – 589
-
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsIn: Clinical Cancer Research , Jg. 20 2014, Nr. 16, S. 4251 – 4261
-
Reply to M. Perier-Muzet et al [Safety and Management of New Primary Melanomas During Receipt of BRAF Inhibitors ]In: Journal of Clinical Oncology (JCO) , Jg. 32 2014, Nr. 28, S. 3203 – 3204
-
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology , Jg. 28 2014, Nr. 12, S. 1685 – 1689
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI) , Jg. 106 2014, Nr. 9
-
TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomasIn: Modern Pathology , Jg. 27 2014, Nr. 4, S. 502 – 508DOI (Open Access)
-
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaIn: Cancer Discovery , Jg. 4 2014, Nr. 1, S. 94 – 109
-
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition : MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsIn: European Journal of Cancer (EJC) , Jg. 50 2014, Nr. 2, S. 406 – 410
-
23. Jahrestagung der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) - Deutscher Hautkrebskongress in EssenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 11 2013, Nr. 12, S. 1220 – 1221
-
Autoimmuno-hypophysitis, Autoimmuno-colitis and Autoimmuno-hepatitis in a Patient with metastatic Melanoma during Therapy with CTLA-4 Antibody IpilimumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 11 2013, Nr. 9, S. 932
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) , Jg. 31 2013, Nr. 30, S. 3844 – 3845
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research , Jg. 19 2013, Nr. 22, S. 6331 – 6332
-
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre 2013, Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 – 143DOI, Online Volltext (Open Access)
-
Immune-related hypophysitis in three patients with metastatic melanoma undergoing Ipilimumab treatmentIn: Experimental and Clinical Endocrinology & Diabetes , Jg. 121 2013, S. P10
-
Isolated cerebral susceptibility artefacts in patients with malignant melanoma : Metastasis or not?In: European Radiology , Jg. 23 2013, Nr. 9, S. 2622 – 2627
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 11 2013, Nr. 9, S. 952 – 952
-
Lack of SF3B1 R625 mutations in cutaneous melanomaIn: Diagnostic Pathology , Jg. 8 2013, S. 87DOI (Open Access)
-
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinomaIn: PLoS ONE , Jg. 8 2013, Nr. 11, S. e80354DOI (Open Access)
-
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumoursIn: British Journal of Cancer (BJC) , Jg. 109 2013, Nr. 2, S. 497 – 501DOI (Open Access)
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology , Jg. 23 2012, Nr. Suppl. 10, S. x104 – x108
-
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology (JCO) , Jg. 30 2012, Nr. 19, S. 2375 – 2383
-
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 10 2012, Nr. 5, S. 319 – 325
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology , Jg. 13 2012, Nr. 11, S. 1087 – 1095
-
Nebenwirkungsmanagement von AfatinibIn: TumorDiagnostik & Therapie , Jg. 33 2012, Nr. 3, S. 154 – 161
-
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology , Jg. 148 2012, Nr. 3, S. 357 – 361
-
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 10 2012, Nr. 7, S. 475 – 486
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW , Jg. 136 2011, Nr. 1-2, S. 39 – 44
-
Failure to detect production of IL-10 by activated human neutrophilsIn: Nature Immunology , Jg. 12 2011, Nr. 11, S. 1017 – 1018
-
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs , Jg. 19 2010, Nr. 11, S. 1439 – 1449
-
Adjuvant treatment of patients with stage III melanoma : 4-year follow-up time of multicenter real-world study
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S740 -
Analysis of gender-specific Differences in Response to First-line Treatment with Immunotherapy or targeted Therapy in Melanoma Patients with metastatic Stage IV Melanoma : An ADO/DeCOG Study of 2032 Patients from the prospective, multicenter Skin Cancer Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 16 – 17
-
Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S733 – S734 -
Clinical Characteristics and Survival Data of Patients with advanced Merkel Cell Carcinoma (MCC) treated with Avelumab : Analysis of a prospective German MCC Registry (MCC TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 11 – 12
-
Correlation of Laboratory Parameters at the Start of adjuvant Treatment of Stage III Melanoma Patients with clinical Outcome : A multicenter Real World StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 8 – 9
-
Deciphering unresectable in-transit metastasis in melanoma : Multi-modal and longitudinal insightsIn: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S736
-
Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma : Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
ESMO Congress 2024, 13-17 September 2024, Barcelona, Spain,In: Annals of Oncology , Jg. 35 2024, Nr. Suppl. 2, S. S1235 – S1236 -
PD-L1 Expression in Lymph Node Metastases as a Predictor of adjuvant Immunotherapy Success in Stage III Melanoma Patients: An Analysis of the prospective ADOREG Study TRIM-ADJUVANTIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 15 – 16
-
Survivorship after Skin Cancer Care Situation in Germany, Austria and SwitzerlandIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 25
-
The PD-L1 Expression predicts the Outcome of anti-PD-1/PD-L1-based Immune Checkpoint Therapy in Patients with metastatic Merkel Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 22 2024, Nr. Suppl. 4, S. 17 – 18
-
A low interventional trial addressing the immunological effects of the RANKL-inhibitor Denosumab in combination with dual checkpoint blockade in melanoma patients with bone involvement reveals upregulation of CXCL-13
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 17DOI (Open Access) -
A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma : First results from the AliCe study
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S654 – S655 -
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 – 22DOI (Open Access) -
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 – 28DOI (Open Access) -
Langzeitergebnisse nach hypofraktionierter ablativer Präzisionsbestrahlung bei Patienten mit multiplen cerebralen MetastasenIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S124DOI (Open Access)
-
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21DOI (Open Access) -
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 – 9DOI (Open Access) -
Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC) : Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology , Jg. 33 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S903DOI (Open Access) -
Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED) : Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology , Jg. 33 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S900DOI (Open Access) -
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 13 – 14 -
Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 18 – 19 -
Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1–based immunotherapyIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl., S. 9575DOI (Open Access)
-
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl., S. 9548
-
Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanomaIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl., S. e21533DOI (Open Access)
-
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 12 – 13 -
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie , Jg. 76 2022, Nr. Supplement 1, S. S52 -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 6 -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl., S. 9570DOI (Open Access)
-
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 16 – 17 -
REINA - Retrospective Multicenter ADOReg Evaluation of Ipilimumab plus Nivolumab in Avelumab-refractory Merkel cell carcinoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 21 -
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 3 -
Which patients should receive adjuvant treatment : an analysis of stage IIA-IIIA patients of the CMMR
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 19 -
Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)In: Annals of Oncology , Jg. 32 2021, Nr. Suppl. 5, S. 873 – S874DOI (Open Access)
-
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ) 2021, OA4240DOI (Open Access)
-
Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)In: Annals of Oncology , Jg. 32 2021, Nr. Suppl. 5, S. 877 – S878DOI (Open Access)
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 59 – 60
-
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 19
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell Carcinoma
31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, Hamburg, Germany and Virtual,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 23DOI (Open Access) -
Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patientsIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 9533 – 9533DOI (Open Access)
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 6 – 7
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 31
-
Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications : A retrospective, multicenter ADOReg StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 15 – 16
-
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma : Final results from the dose-finding phase I part of the IMMU-Target trialIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 9532 – 9532DOI (Open Access)
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 58 – 59
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28DOI (Open Access)
-
Apoptotische Gastritis nach Immuncheckpointblockade : Ein typisches histopathologisches MusterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P12DOI (Open Access)
-
Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)
Annual Meeting of the American Association for Cancer Research (AACR), COVID-19 and Cancer, July 20-22, 2020, Virtual,In: Clinical Cancer Research , Jg. 26 2020, Nr. 18 Suppl., S. 02 – 01DOI (Open Access) -
Delayed immune-related adverse events (irAEs) on anti-PD1-based therapyIn: Annals of Oncology , Jg. 31 2020, Nr. Suppl. 4, S. S761 – S762DOI (Open Access)
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06DOI (Open Access)
-
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49DOI (Open Access)
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36DOI (Open Access)
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08DOI (Open Access)
-
Immun‐Checkpoint‐Blockade beim Merkelzellkarzinom : Klinische und molekulare Biomarker‐AnalyseIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV22DOI (Open Access)
-
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapyIn: Journal of Clinical Oncology (JCO) , Jg. 38 2020, Nr. 15_Suppl., S. 10005DOI (Open Access)
-
Melanoma recurrence after adjuvant targeted therapy : A multicenter analysisIn: Journal of Clinical Oncology (JCO) , Jg. 38 2020, Nr. 15_Suppl., S. 10016DOI (Open Access)
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44DOI (Open Access)
-
PD1‐Inhibitoren bei fortgeschrittenem kutanem Plattenepithelkarzinom : „Real World“‐Daten einer retrospektiven, multizentrischen StudieIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV20DOI (Open Access)
-
Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction
ESC Congress 2020 – The Digital Experience 29 August – 1 September 2020,In: European Heart Journal , Jg. 41 2020, Nr. Supplement_2, S. 3260DOI (Open Access) -
SERIO – Side Effect Registry Immuno‐Oncology : Nebenwirkungsregister für seltene, schwere und komplexe Nebenwirkungen von ImmuntherapienIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV27DOI (Open Access)
-
The nature and management of acquired resistance to PD1-based therapy in melanomaIn: Journal of Clinical Oncology (JCO) , Jg. 38 2020, Nr. 15_Suppl., S. 10014DOI (Open Access)
-
The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibitionIn: Annals of Oncology , Jg. 31 2020, Nr. Suppl. 4, S. S733 – S734DOI (Open Access)
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 18 2020, Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43DOI (Open Access)
-
Variants in CD5 and IRF4 impact into melanoma survivalIn: European Journal of Human Genetics , Jg. 26 2019, Nr. Suppl., S. 688 – 689DOI (Open Access)
-
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC) : A randomized, multicenter DeCOG/ADO studyIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. Suppl. 15, S. 9527DOI (Open Access)
-
Adjuvante Therapie des Merkelzellkarzinoms mit Ipilimumab im Vergleich zur Beobachtung (ADMEC) : eine randomisierte, multizentrische ADO‐Studie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 6DOI (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 61 – 62DOI (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 26 – 27DOI (Open Access) -
BRAF/MEK inhibition in melanoma patients with rare BRAF mutationsIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. Suppl. 15, S. 9542 – 9542DOI (Open Access)
-
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 49 – 50DOI (Open Access) -
Charakterisierung des Checkpoint‐Inhibitor‐assoziierten Diabetes mellitus – Erfahrungen bei 12 Patienten
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 15 – 16DOI (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. Suppl. 6, S. 3
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 7 – 8DOI (Open Access)
-
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 28 – 29DOI (Open Access) -
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapyIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. Suppl. 15, S. 9545 – 9545DOI (Open Access)
-
Hyponatriämie und Nephritis – seltene Nebenwirkungen von Checkpointinhibitoren bei Patienten mit metastasiertem Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 15DOI (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 3DOI (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 11 – 12DOI (Open Access) -
Mundtrockenheit unter Immuncheckpoint‐Inhibitoren: eine Analyse von 29 Patienten aus 10 deutschen Hautkrebszentren
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 10 – 11DOI (Open Access) -
NICO ‐ eine nationale, prospektive, nicht‐interventionelle Studie (NIS) mit Nivolumab als Monotherapie oder in Kombination mit Ipilimumab bei Patienten mit fortgeschrittenem (inoperablem oder metastasiertem) Melanom zur Erhebung von real‐world data
Konferenz 28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 79DOI (Open Access) -
Neuromuskuläre Nebenwirkungen von Immuncheckpoint‐Inhibitoren
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 9 – 10DOI (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 38DOI (Open Access) -
Real-world evidence in melanoma : A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 1, S. 159DOI (Open Access) -
The utility of chemotherapy after immunotherapy failure in metastatic melanoma : A multicenter case series.In: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. 15 Suppl., S. e21588DOI (Open Access)
-
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 16 2018, Nr. S6, S. 28DOI (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 15 2017, Nr. Suppl. 3, S. 26 – 27
-
Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroupsIn: Journal of Clinical Oncology (JCO) , Jg. 32 2014, Nr. 15, Suppl., S. 9031
-
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 44DOI (Open Access) -
Ausgedehntes Rezidiv eines atypischen Fibroxanthoms
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 99DOI (Open Access) -
Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab : Analysis of a prospective German MCC registry (MCC TRIM)
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S685 – S686 -
Langfristiger Therapieerfolg von sequentieller Immun- und zielgerichteter Therapie beim metastasierten malignen Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 47 – 48DOI (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 – 77DOI (Open Access) -
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
ESMO Congress 2023 ; 20 - 24 October 2023 Madrid, Spain,In: Annals of Oncology , Jg. 34 2023, Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S694DOI (Open Access) -
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 – 100DOI (Open Access) -
Therapieoption beim lokal fortgeschrittenen kutanen Plattenepithelkarzinom nach Cemiplimab-Resistenz
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 21 2023, Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 72DOI (Open Access) -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 84 -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 29 – 30 -
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity : A multicenter case series
2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) ; June 3-7, 2022, Chicago, Ill., USA and virtual,In: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 16_Suppl.: 2022 ASCO Annual Meeting, S. 2665DOI (Open Access) -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 88 -
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 44 – 45 -
Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology , Jg. 33 2022, Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S924 – S925DOI (Open Access) -
Tolerability and efficacy of BRAF and MEK inhibitors for metastasized melanoma after intra-class switch : a multicenter, retrospective study
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 20 2022, Nr. S3, S. 28 – 29 -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic Melanoma
31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, Hamburg, Germany and Virtual,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) , Jg. 19 2021, Nr. Suppl. 4, S. 75 – 76DOI (Open Access)